NCT07173348 Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea
| NCT ID | NCT07173348 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Geneva |
| Condition | Cancer (With or Without Metastasis) |
| Study Type | INTERVENTIONAL |
| Enrollment | 82 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2028-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 82 participants in total. It began in 2026-04-01 with a primary completion date of 2028-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Persistent dyspnea is a debilitating symptom, that is common and difficult to treat. This symptom is found in many different diseases including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), chronic heart failure (CHF), and metastatic cancer. Dyspnea is associated with many other symptoms, including anxiety, depression, and fatigue and is responsible for a significant reduction in quality of life. To date, only opiates are recommended for the pharmacological treatment of persistent dyspnea. The effectiveness of hypnosis is well known in the treatment of anxiety and delivered to patients suffering from chronic dyspnea for this reason. One randomised controlled study has shown that a single 20-minute mindfulness sessions could significantly reduce general symptom burden and have a significant impact on anxiety and depression in palliative care patients. Furthermore, the intervention had no negative side effects. Our aim is to evaluate the effectiveness of three hypnosis sessions on breathlessness mastery in patients with persistent dyspnea, using as a primary outcome the mastery domain of a validated tool, the Chronic Respiratory Questionnaire (CRQ).
Eligibility Criteria
Inclusion Criteria: * Patients aged ≥ 18 years and * Primary diagnosis of metastatic cancer, COPD stage at least B or E, ILD, or CHF and * Dyspnea stage NYHA ≥ II or mMRC ≥ 2 Exclusion Criteria: * Have had hypnosis treatment in the last 12 months * Have an estimated life expectancy of less than 6 months * Have participated in pulmonary rehabilitation in the last 6 months * Have been hospitalised in the last month (30 days) * Are unable to come to the hospital for 3 outpatient consultations (1 every two weeks) * Have a condition that would interfere with their ability to respond to the questionnaires (i.e. cognitive impairment, hearing impairment, etc.) * Are not eligible for a hypnosis session due to a psychiatric disorder
Contact & Investigator
Lisa Hentsch, Dr med
PRINCIPAL INVESTIGATOR
University Hospital, Geneva
Frequently Asked Questions
Who can join the NCT07173348 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer (With or Without Metastasis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07173348 currently recruiting?
Yes, NCT07173348 is actively recruiting participants. Contact the research team at lisa.hentsch@hug.ch for enrollment information.
Where is the NCT07173348 trial being conducted?
This trial is being conducted at Geneva, Switzerland.
Who is sponsoring the NCT07173348 clinical trial?
NCT07173348 is sponsored by University Hospital, Geneva. The principal investigator is Lisa Hentsch, Dr med at University Hospital, Geneva. The trial plans to enroll 82 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.